{"entity":{"id":"plerixafor","kind":"drug","name":"Plerixafor","aka":["AMD3100"],"tldr":"Plerixafor (Mozobil) is an injection given with G-CSF to flush stem cells out of the bone marrow into the blood so that enough can be collected for an autologous transplant in myeloma or lymphoma.","summary":"Plerixafor was approved by the FDA in December 2008 in combination with filgrastim to mobilise haematopoietic stem cells for collection and autologous transplantation in non-Hodgkin lymphoma and multiple myeloma, on two placebo-controlled phase 3 trials in which the proportion of patients reaching the target cell dose in few apheresis sessions roughly doubled; the EU authorised Mozobil in 2009 and a paediatric extension followed. It is used routinely for poor mobilisers and increasingly pre-emptively, and the same CXCR4 blockade underlies its investigation to mobilise stem cells for gene therapy and to sensitise leukaemia to chemotherapy. Motixafortide (Aphexda, 2023) is a longer-acting CXCR4 antagonist for the same purpose. Diarrhoea, nausea and injection-site reactions are common.","status":"approved","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Plerixafor","links":[{"label":"US label (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=plerixafor"},{"label":"NCI drug page","url":"https://www.cancer.gov/about-cancer/treatment/drugs/plerixafor"},{"label":"EPAR","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/mozobil"}],"tags":["nci-list","supportive"],"related":["filgrastim"],"cancers":["multiple-myeloma","dlbcl","follicular-lymphoma","mantle-cell-lymphoma"],"sections":[],"technologies":["autologous-stem-cell-transplant","apheresis-starting-material"],"targets":["cxcr4"],"drugs":[],"companies":["sanofi"],"institutions":[],"pathways":[],"terms":[],"trials":["nct00103662","nct01301963","nct01767714"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Mozobil","modality":"Small-molecule CXCR4 antagonist (stem cell mobiliser)","supportive":true,"mechanism":"Bicyclam that reversibly blocks CXCR4 binding of stromal-derived factor-1 (CXCL12), releasing haematopoietic stem cells from bone marrow niches into the blood within hours.","approvals":[{"region":"US","year":2008,"indication":"Stem cell mobilisation with filgrastim for autologous transplantation in NHL and multiple myeloma"},{"region":"EU","year":2009,"indication":"Stem cell mobilisation with G-CSF in lymphoma and multiple myeloma with poor mobilisation (Mozobil)"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/plerixafor/","neighbours":{"drug":[{"id":"filgrastim","kind":"drug","name":"Filgrastim (G-CSF)","route":"/drugs/filgrastim/"},{"id":"motixafortide","kind":"drug","name":"Motixafortide","route":"/drugs/motixafortide/"}],"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"},{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"technology":[{"id":"apheresis-starting-material","kind":"technology","name":"Apheresis and starting-material collection","route":"/technologies/apheresis-starting-material/"},{"id":"autologous-stem-cell-transplant","kind":"technology","name":"Autologous stem cell transplant (high-dose therapy)","route":"/technologies/autologous-stem-cell-transplant/"}],"target":[{"id":"cxcr4","kind":"target","name":"CXCR4","route":"/targets/cxcr4/"}],"company":[{"id":"sanofi","kind":"company","name":"Sanofi","route":"/companies/sanofi/"}],"trial":[{"id":"nct01767714","kind":"trial","name":"Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation","route":"/trials/nct01767714/"},{"id":"nct01301963","kind":"trial","name":"Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide","route":"/trials/nct01301963/"},{"id":"nct00103662","kind":"trial","name":"Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients","route":"/trials/nct00103662/"}]}}